Grants & Programs

For Philanthropic Backers

CRI's Venture Fund trial and partnership pipeline for the coming year is extraordinarily robust and we continue to seek new philanthropic backers to support this novel model and accelerate the development of better immunotherapies for more types of cancer. 

Fund Objectives

Financing for the Clinical Accelerator's portfolio of trials and reagents is provided by the Cancer Research Institute Venture Fund, CRI's donor-supported venture capital arm. This unique non-profit investment vehicle serves two key functions: 1) to negotiate access to top industry-owned drugs, and 2) invest in the most promising CVC clinical studies that include those drugs.

The venture fund works with Ludwig Cancer Research to strike partnerships with leading biopharma companies whereby the CVC is provided with access to company-owned drugs in return for the drug development benefits of the collaboration's resources—distinguished expertise in clinical immunology, accelerated patient recruitment, in-house clinical trials management, and the venture fund's nonprofit financing for trials.

Each venture fund investment covers some or all of the costs of an important clinical study of a drug (or drugs) identified as a top priority by the CVC's global scientific membership. CRI's venture funds return on investment structure is both non-dilutive and back-ended, helping to de-risk the critical early stages of development of potentially transformative new treatments that otherwise would not likely be initiated, while also empowering CVC researchers to answer key clinical questions today that otherwise might not be answerable for years (or decades). 

Over time, by backing the development of the best new drugs, in partnership with well-capitalized companies, the venture fund accelerates development of new treatments for patients while also positioning the fund to generate significant returns on investment so that the model can become self-sustaining.

Join a Distinguished Community of Investors

Lead Founding Directors

  • Michael M. Kellen, Co-President, Arnhold & S. Bleichroeder Holdings
  • Donald J. Gogel, President & CEO, Clayton, Dubilier & Rice
  • Lief D. Rosenblatt, Manager, ENE Investco Management
  • Paul C. Shiverick, Partner, Seminole Management Co
  • Howard Schiller, Executive VP & CFO, Valeant Pharmaceuticals
  • Richard M. DeMartini, Managing Director, Crestview Partners
  • Brian Riano, CEO, Claren Road Asset Management
  • Frank V. Sica, President, Tailwind Capital

Founding Directors

  • Edgar R. Berner, Partner, John Lang, Inc.
  • Peter L. Bloom, Managing Director, General Atlantic
  • James M. Citrin, Co-Leader, Board & CEO Practice, Spencer Stewart
  • Geoffrey O. Coley, International Business Head, Mitsubishi UFJ Securities (USA), Inc.
  • John B. Fitzgibbons, Owner, Basin Holdings US LLC
  • Alexander P. Lynch, Partner, White Deer Energy
  • James F. McCann, Founder and CEO,
  • Thomas G. Mendell, Owner, T.G. Mendell Corp.
  • Andrew M. Paul, Managing GP, Enhanced Equity Funds
  • Michael B. Targoff, CEO, Loral Space and Communications

Interested in Learning More?

You can experience a new kind of results-driven philanthropy that's guaranteed to significantly move the needle in cancer research.

Contact Cancer Research Institute Venture Fund managing director Adam Kolom at or by calling (212) 792-5214.